SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of ...
Last week, QuidelOrtho Corporation QDEL announced the availability of QUICKVUE Influenza + SARS Test. The CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay is the latest addition to the ...
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, ...
(RTTNews) - QuidelOrtho (QDEL) said it has received FDA 510(k) clearance for QuickVue COVID-19 test. The clearance allows the test to be used in home and medical facility settings with CLIA ...
QuidelOrtho Corporation QDEL recently announced the FDA 510(k) clearance for its QuickVue COVID-19 test.With CLIA certificates of waiver, this approval permits the test to be used accurately and ...
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 ...
In a recent study posted to the medRxiv* server, a team of researchers investigated how antigen concentration and viral load in different specimen types affected the performance of severe acute ...
QuidelOrtho (QDEL) is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)-cleared rapid, easy-to-use immunoassay designed for professional use in physician ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback